Decellularized Amniotic Membrane Hydrogel for Stem Cell Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current regenerative strategies using stem cells face limitations due to poor cellular survival, distribution, and integration after transplantation, particularly due to inadequate methods for stem cell delivery and integration into tissue injury sites, and there is a lack of a human-derived hydrogel matrix for human stem cell culture and delivery.
Innovation Solution
The development of a decellularized amniotic membrane-derived extracellular matrix (AM-ECM) hydrogel, which can be used as a scaffold for stem cell delivery and tissue engineering, is processed from placental tissue, providing a biocompatible and immunoregulatory matrix for stem cell expansion and integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are transplanted without a delivery scaffold, then the transplantation procedure is simple, but cellular survival, distribution, and integration are poor
Solution Approach 1:
The patent introduces decellularized amniotic membrane as an intermediary scaffold between the stem cells and the injury site. This scaffold serves as a delivery vehicle that maintains cell viability during transplantation and facilitates integration into the target tissue, directly resolving the contradiction between simple transplantation and effective cell integration.
Solution Approach 2:
The decellularized amniotic membrane scaffold possesses a porous structure that allows nutrient diffusion, waste removal, and cell infiltration. This porous architecture supports cellular survival and distribution while maintaining structural integrity, addressing the contradiction between simple delivery and effective cell integration.
2Reliability
If a hydrogel matrix is used for stem cell culture, then cell delivery and integration are improved, but there is a lack of human-derived hydrogel matrix options
Solution Approach 1:
The patent extracts the extracellular matrix components from human amniotic membrane through decellularization, removing cellular material while preserving the functional matrix. This extracted human-derived ECM serves as a versatile hydrogel matrix for stem cell culture and delivery, resolving the contradiction between delivery effectiveness and availability of human-derived options.
Solution Approach 2:
The decellularized amniotic membrane hydrogel matrix demonstrates multi-functionality by serving as both a structural scaffold and a biological active matrix that supports stem cell culture, delivery, and integration. This universal application across different stem cell types and injury models addresses the contradiction between delivery effectiveness and versatility.
3Adaptability or versatility
If allogeneic stem cells are used for therapy, then the treatment can be applied broadly, but immune rejection occurs
Solution Approach 1:
The patent utilizes the decellularization process to remove immunogenic cellular components from the amniotic membrane while preserving the beneficial extracellular matrix structure. This converts the potential harm of immune rejection into a benefit by creating an immunomodulatory scaffold that reduces immune responses to allogeneic stem cell transplantation.
Solution Approach 2:
The patent changes the physical and chemical parameters of the amniotic membrane through decellularization and hydrogel formation, transforming it from a cellular tissue into an acellular, immunomodulatory matrix. This parameter change eliminates MHC class II expression and other immunogenic features while maintaining structural integrity, resolving the contradiction between broad treatment applicability and immune rejection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AM-ECM hydrogel supports stem cell viability, proliferation, and secretion of therapeutic factors, facilitating tissue repair and regeneration while avoiding immune rejection, and demonstrates effectiveness in preventing adhesions and promoting vascularization.
Implementation Method 1
the isolated DCM is processed by freezing, freeze drying, lyophilization and/or micronized into powder
Implementation Method 2
the isolated DCM is processed by freezing, freeze drying, lyophilization and/or micronized into powder
Data Source
AI summary
Provided herein is an isolated decelluarized amniotic membrane (DCM) and methods for using same therapeutically in vivo and in vitro. In one aspect, the isolated DCM is further processed, freezing, freeze drying, lyophilization micronized into powder or treatment with pepsin to create a hydrogel.